Alkermes plc

Stories

Alkermes unveils ADHD data for orexin drug, expanding the class beyond sleep disorders

As of September 2026: Developing orexin agonists across sleep, ADHD and fatigue

Alkermes presented its orexin agonist as an ADHD treatment on September 21, the first time the new drug class has moved into a mainstream psychiatric market. The company calls the program a potential 'company changer.'

Updated Sep 21

Alkermes enters sleep medicine market through Avadel acquisition

Money Moves

As of May 2026: Acquirer, now owns Avadel and LUMRYZ

Alkermes, a neuroscience-focused pharmaceutical company, completed its $2.37 billion acquisition of Avadel Pharmaceuticals on February 12, 2026, gaining immediate entry into the sleep medicine market. The deal adds LUMRYZ, the only once-nightly narcolepsy treatment, to Alkermes' portfolio alongside an emerging pipeline of orexin-based therapies.

Updated May 27